Healthcare >> CEO Interviews >> September 23, 2003
FRIEDHELM BLOBEL is President and Chief Executive Officer at Gryphon
Therapeutics, Inc., a private company located in South San Francisco,
California. Dr. Blobel joined the company in July 2000 in order to
execute Gryphon's business plan focused on the development of
performance-enhanced protein therapeutics. He served in several
executive capacities at Hoechst as well as Boehringer Mannheim for more
than 20 years. These roles included Group President of several product
divisions, Chief Technology Officer, General Manager of a Marketing and
sales joint venture with Yamanouchi in Tokyo, Japan, and Senior VP of
R&D for Diabetes and Patient Care in Mannheim, Germany as well as
Indianapolis. Dr. Blobel holds a PhD in Biochemistry and Microbiology
from the University of Hohenheim, Germany, and an advanced degree in
Chemistry and Biochemistry from the University of Stuttgart, Germany. Profile
Therapeutics?
Dr. Blobel: The company was founded in 1994. In the first couple of
years the company pursued a different
